COMPANY PROFILE

Naurex

Explore full profile

Developing novel modulators of the NMDA receptor to treat challenging diseases of the brain and central nervous system

Evanston, United StatesFounded 2008Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2015

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Naurex

Naurex, a subsidiary of AbbVie, operates in the biopharmaceutical sector, focusing on developing and delivering advanced therapies for complex medical conditions. The company primarily serves healthcare providers and patients, aiming to address unmet medical needs through innovative solutions. Naurex operates in a highly regulated market, adhering to stringent legal and clinical guidelines to ensure the safety and efficacy of its products. The business model revolves around extensive research and development (R&D), clinical trials, and strategic partnerships to bring new treatments to market. Revenue is generated through the sale of approved therapies, licensing agreements, and collaborations with other pharmaceutical entities. Naurex's core competencies include expertise in biologics, small molecules, and novel drug delivery systems, positioning it as a leader in the biopharmaceutical industry.

Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2008
Headquarters: Evanston, United States
Employees: 11
Open positions: None listed
Dealroom signal: 77.2/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Supply Chain Management, Testing, Risk Management, Biotechnology, Neurology, Mental Health, Spinout, Biotech and Pharma, medical testing, DT and LS
Business model: Manufacturing
Client focus: b2c
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

7 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITIONOther financing	Jul 2015	$560M	$560M	Allergan	—
SERIES COther financing	Dec 2014	$80M	$320M	Cowen Group · Latterell Venture Partners · Takeda Ventures · Savitr Capital	—

Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

Naurex website traffic

Latest recorded traffic for Naurex is 16K monthly website visits. Naurex's team grew 57.1% over the past year.

Latest monthly visits16K 1-year team growth+57.1%

Monthly website visitsApr 2016–Jan 2023

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ANANTERIOSInnovative biopharmaceutical solutions tackling the toughest health challenges with a focus on impactful treatments	New York City, United States	Acquired	3	$25M	$90M
SPSera PrognosticsProviding individualized risk assessment to predict and manage premature birth, preeclampsia, and other pregnancy complications	Salt Lake City, United States	Operational
MImiDiagnosticsSilicon chip diagnostics for rapid, lab-quality results	Leuven, Belgium	Operational
ATAvalo TherapeuticsDiscovers, develops and commercializes neuroscience drugs	Rockville, United States	Operational
IPImpel PharmaceuticalsDevelops a drug delivery device for central nervous system (CNS) disorders	Seattle, United States	Acquired
TWtwoXARImproving Health Through Computation	Palo Alto, United States	Operational
IOioveraMyoScience develops and commercializes technology-driven dermatological products	Fremont, United States	Acquired
KGKailos GeneticsConsumers access to affordable physician-ordered genetic tests	Huntsville, United States	Acquired